← Back to Clinical Trials
Recruiting NCT06631781

NCT06631781 Cognitive Control Mechanisms in Older Adults

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06631781
Status Recruiting
Phase
Sponsor Hebrew University of Jerusalem
Condition Depressive Symptoms
Study Type INTERVENTIONAL
Enrollment 42 participants
Start Date 2024-02-02
Primary Completion 2024-12

Trial Parameters

Condition Depressive Symptoms
Sponsor Hebrew University of Jerusalem
Study Type INTERVENTIONAL
Phase N/A
Enrollment 42
Sex ALL
Min Age 65 Years
Max Age N/A
Start Date 2024-02-02
Completion 2024-12
Interventions
GOLD-Cog+

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The prevalence of depressive symptoms in older adults is on the rise, affecting 13 to 37% of older adults globally. These symptoms significantly impact health, increasing the risk of dementia and cognitive decline, and impairing daily functioning and quality of life. Reduced cognitive control (CC) is a key factor contributing to depressive symptoms, affecting 40% of adults with such symptoms. Despite this, over half of affected adults do not respond well to available treatments. Computerized cognitive training (CCT) has shown efficacy in improving CC but its impact on daily functioning is limited. The Cognitive Orientation to Occupational Performance (CO-OP) approach has demonstrated promise in improving daily functioning, as measured by occupational performance (OP). We propose a novel intervention, GOLD-Cog+, combining CCT and CO-OP, to address CC and functional deficits in older adults with depressive symptoms.

Eligibility Criteria

Inclusion Criteria: * Depressive Symptoms based on Patient Health Questionnaire (PHQ-8) ≥ 5 * Healthy Cognition based on Montreal Cognitive Assessment (MoCa) ≥ 20 * Capable of signing and agreeing to participate in the study * Have the basic technological skills to use a tablet based on self-report * Adequate sight and hearing abilities (with assistive technology) to be able to use a tablet and fully participate in a small group setting (6 people) * Ability to fluently read, speak and understand Hebrew or English Exclusion Criteria: * Any neurodegenerative disorder (e.g., Mild Cognitive Impairment (MCI), Dementia, Parkinson's disease) via self-report * Psychiatric disorders, not including depression or anxiety disorders (specifically: Schizophrenia, Bipolar or Psychotic disorders) via self-report

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology